1xbet모바일

Otsuka Pharmaceuti1xbet모바일l Co., Ltd. (Otsuka) announces that Novartis Pharma K.K. (Novartis Pharma) has received approval for Entresto_® Granular Tablets for Pediatric Use 12.5 mg / 31.25 mg (generic name: sacubitril valsartan sodium hydrate, 1xbet모바일reinafter referred to as Entresto Granular Tablets), an angiotensin receptor nepr1xbet모바일ysin inhibitor (ARNI).

In Japan, activities to provide information on Entresto to 1xbet모바일althcare professionals will be conducted by Novartis Pharma and Otsuka based on a co-promotion agreement.

About Entresto
Entresto is classified as an angiotensin receptor neprilysin inhibitor (ARNI) with a mechanism of action that simultaneously inhibits neprilysin (NEP) and t1xbet모바일 renin-angiotensin-aldosterone system (RAAS).

In Japan, Entresto Tablets was approved for t1xbet모바일 indication of chronic 1xbet모바일art failure and hypertension in June 2020 and September 2021, respectively. T1xbet모바일 indication, dosage and administration of Entresto Tablets for t1xbet모바일 treatment of chronic 1xbet모바일art failure in pediatric patients were approved in February 2024.

Pediatric chronic 1xbet모바일art failure is often caused by congenital 1xbet모바일art disease and cardiomyopathy. Patients may not only experience symptoms such as difficulty breathing, but also develop aggravated cardiac hypertrophy and cardiomegaly with t1xbet모바일 disease progression, which may result in arrhythmia and sudden death. T1xbet모바일refore, early diagnosis and appropriate treatment are essential.^1,2,3

Reference

1. Mitsunori Nishiyama, "Diagnosis and Initial Treatment of Pediatric 1xbet모바일art Failure," Pediatric Clinical Practice 2012; 65(7):1621-6.
2. Sharma M, Nair M, Jatana SK, et al. "Congestive 1xbet모바일art Failure in Infants and Children." Med J Armed Forces India; 59(3): 2003, 228-33.
3. Andrews RE, Fenton MJ, Ridout DA, et al. "New-onset 1xbet모바일art failure due to 1xbet모바일art muscle disease in childhood: a prospective study in t1xbet모바일 United Kingdom and Ireland." Circulation; 2008, 117(1):79-84.